Resveratrol is a kind of plant polyphenols with various bioactivities， which can improve and prevent nonalcoholic fatty liver disease(NAFLD) by reducing oxidative stress and lipid deposition. However， resveratrol is insoluble in water， resulting in low oral bioavailability. In this study， resveratrol was embedded in lysozyme micelles catalyzed by glutamine transaminase. the critical micelle concentration of the carrier was 1.1 μg/mL and the particle size was 58 nm， and the drug loading of resveratrol was increased to 21.2%. In the in vitro digestion model， the carrier was resistant to gastric acid and pepsin， and the resveratrol release rate was 61% after the 120 min intestinal digestion. The max concentration of resveratrol in plasma (Cmax) was increased to 39.9 ng/mL， the area under the curve (AUC0-48 h) was 218.6 ng/mL， and the absolute bioavailability (Fabs) increased to 3%. The intervention effect of resveratrol on NAFLD was investigated by using NAFLD mouse model. The results showed that the body fat rate of NAFLD mice was 1.1 times lower than that of free resveratrol， and the indexes of blood lipids， triglycerides (TG) and free fatty acids (NEFA) in serum， malondialdehyde (MDA) and superoxide dismutase (SOD) in liver tissue were significantly decreased. The results showed that compared with unembedded resveratrol， resveratrol embedded with lysozyme had a better intervention effect on NAFLD in mice.